Look­ing for the next big break­through in CAR-T, Mike Gilman de­buts Ob­sid­i­an with $49.5M round

Biotech en­tre­pre­neur Michael Gilman is now on to his fourth start­up Suzanne Kre­it­er, Boston Globe

Over the past cou­ple of years, the pi­o­neers in the CAR-T field have made some phe­nom­e­nal leaps for­ward, and been hit with some of the most dra­mat­ic set­backs in biotech. They’ve of­fered ad­vanced stage can­cer pa­tients a sec­ond lease on life, and run in­to daunt­ing hur­dles on the out­er lim­its marked by the graves of pa­tients. And now a biotech up­start is grad­u­at­ing from a sub­stan­tial — and very qui­et — seed ef­fort in a dri­ve to the clin­ic with a new tech specif­i­cal­ly de­signed to ad­dress the biggest chal­lenges in CAR-T.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER